Evommune reports zero revenue for Q2 2026, down from $3M in the prior-year period, amid strategic collaboration shifts.
Evommune Inc. (EVMN) reported a Q2 GAAP loss of $0.89 per share, with no revenue for the three and six months ended June 30, 2026. The company attributed the decline to its strategic collaboration, which impacted financial performance.
In the same period last year, Evommune recorded $3M in revenue for the six months ended June 30, 2025, while the three-month period also showed zero revenue. The company did not disclose further details on the collaboration’s financial effects.
Shares showed limited immediate reaction to the earnings release.